Sign In
Free Newsletter
For the win: NJ companies kick off 2024 with new sports partnerships
From helping cold-weather athletes beat dry skin to "egg"ceptional pickleball perks, see which New Jersey brands are getting into the spirit of the game this year.
Novo Nordisk to buy hypertension drug for $1.3B
The medication from KBP Biosciences – which is based in Singapore with U.S. headquarters in Princeton – also has the potential to treat cardiovascular and kidney disease, the companies said.
NJ drugmakers’ products among first targeted for Medicare price negotiations
Pharmaceutical companies, including Merck, Johnson & Johnson and others, are concerned the move will hamper innovation and impede patient access and choice.
Novo Nordisk, Eli Lilly sued over ‘stomach paralysis’ claims
Ozempic is making headlines again, this time for facing a lawsuit from a Louisiana woman who alleges the pharmaceutical companies behind that drug and Mounjaro failed to warn patients about health risks associated with their popular Type 2 diabetes medications.
Potential Wegovy, Ozempic link to suicidal thoughts prompts EU investigation
In a statement, the European Medicines Agency stressed that it is “not yet clear whether the reported cases are linked to the patients’ underlying conditions or other factors,” but noted that the medications “are widely used,” with an exposure of more than 20 million patients annually.
Novo Nordisk takes legal action over copycat versions of Wegovy, Ozempic
The filings come about a month after the FDA warned about the safety risks of using unauthorized versions of the drugs, saying it has received reports of adverse health reactions related to modified, or “compounded,” variations.
FDA warns against off-brand versions of Wegovy, Ozempic
As the semaglutide medications remain in high demand and short supply, many consumers have turned to compounding pharmacies for alternative versions of the popular diabetes and weight loss drugs.
FDA approves Novo Nordisk’s weight-loss drug Wegovy for teens
The medication is the only prescription anti-obesity drug for this age group with once-weekly dosing for patients ages 12 and up.
Side effects may include weight loss – and supply shortages
Novo Nordisk is working to resolve shortages of Ozempic and Wegovy by the end of the year.
